摘要
目的:综述高选择性α1A-肾上腺素受体阻滞剂赛洛多辛在良性前列腺增生(benign prostatic hyperplasia,BPH)治疗中的应用和最新研究进展。方法:检索国内外文献,对文献信息进行系统性分析,总结赛洛多辛的药理学特性和临床应用进展。结果与结论:赛洛多辛对α1A-肾上腺素受体的选择性远高于α1B-肾上腺素受体;赛洛多辛可快速、有效改善BPH患者的国际前列腺症状评分(international prostate symptom score,IPSS)以及最大尿流率(maximum flow rate,Qmax);赛洛多辛总体耐受性良好,心血管不良反应轻微。赛洛多辛的临床应用为快速、高效、安全改善BPH患者下尿路症状(lower urinary tract symptoms,LUTS)、提高BPH患者生活质量提供了治疗新选择。
Objective：To review the application and the latest development of silodosin which is a highly selective α1A-AR antagonist in the treatment of benign prostatic hyperplasia （BPH）.Methods： Multiple databases were searched for the term ‘‘silodosin’’, and a systematic analysis was conducted to review the pharmacological characteristics and the clinical application of silodosin.Results and conclusion： Silodosin has a much higher selectivity to α1A-AR subtype than α1B-AR subtype. Silodosin can improve the BPH patients’international prostate symptom score （IPSS） and maximum lfow rate （Qmax） rapidly. Silodosin is generally well tolerated and is associated with minimal cardiovascular adverse effects. Silodosin provides a new therapeutic selection to improve lower urinary tract symptoms （LUTS） and quality of life of BPH patients.
出处
《临床药物治疗杂志》
2015年第2期24-28,共5页
Clinical Medication Journal
关键词
赛洛多辛
良性前列腺增生
临床应用
silodosin
benign prostatic hyperplasia
clinical application
